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ABSTRACT
Obesity is widely correlated with the incidence of colorectal cancer (CRC). The
exact mechanisms that link obesity to CRC risk have not yet been fully established, and
only a limited number of animal models are available to study pathways involved in
obesity-related colon carcinogenesis. The objective of this study was to determine the
influence of HFD-induced obesity on AOM/DSS-mediated colorectal tumorigenesis,
tumor proliferation, and symptom severity. Male C57BL/6 mice were fed a novel high
fat diet, designed to mimic the standard American diet (12 % saturated fat & 28 %
unsaturated fat), at 4 weeks of age until 16 weeks of age to induce obesity. At 16 weeks
of age HFD-fed mice had significantly increased mean body mass compared to LFD-fed
mice. Thus, mice were obese prior to initiation of CRC. Following treatment with
AOM/DSS, study results indicated no significant changes in tumor number or size with
obesity. Similarly, obesity did not increase the severity of symptoms in this model.
These findings challenge previously published data, with the caveat that the low number
of tumors detected in the present model limits translational implications for tumor
characteristics and symptom severity in obesity.
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CHAPTER 1
INTRODUCTION
As the second leading cause of cancer-related deaths for both men and women in
the United States, colorectal cancer (CRC) is a national burden. It is the third most
commonly diagnosed cancer and is of increasing health concern to a growing aging
population 1,2. It has been shown in epidemiological studies that obesity and metabolic
syndromes, like hyperglycemia, hypertension, and hyperlipidemia, increase the risk of
developing CRC 3. As such, lifestyle factors such as limited physical activity,
consumption of food with high fat/limited fiber content, high caloric intake, and obesity
are controllable factors that can influence the development of CRC 4. Conversely, it has
been demonstrated that behavioral factors like exercise and consumption of fruits and
vegetables, even among obese individuals, can reduce the incidence of CRC 4. While
family history is a large component in determining CRC risk, environmental factors are
responsible for the majority of cases. In fact, sporadic CRC, the most prominent form of
CRC that occurs due to an accumulation of mutations in genes regulating the growth and
proliferation of colonic epithelial cells is influenced largely by environmental factors
independent of genetic background 5.
Obesity is widely correlated with the incidence of CRC 6. The exact mechanisms
that link obesity to CRC risk have not yet been fully elucidated; however, a number of
biochemical changes associated with obesity have been implicated and include
inflammatory mediators, adipokines and metabolic markers among others. For example
1

leptin that is upregulated in obese individuals is a hormone and cytokine produced
primarily by adipocytes has been shown to induce CRC by a variety of different
pathways 4. Similarly, increased plasma levels of insulin observed during obesity disrupt
normal metabolic processes and thought to activate pathways involved in oncogenesis 4.
In addition, inflammatory mediators that are increased in adipose tissue have been linked
to every step involved in the development and promotion of CRC. While there is an
abundance of obesity-mouse models, the number of models available to study pathways
involved in colon carcinogenesis is limited 3.
Among the chemically induced CRC models, the azoxymethane (AOM) and
dextran sodium sulfate (DSS) model has been proven to induce CRC in a shortened
amount of time with a high level of reproducibility 7. This outstanding model has been
utilized in a variety of studies investigating the histopathologic and molecular features
involved in carcinogenesis as well as determining chemopreventive and therapeutic
approaches in combating CRC 7. The purpose of this current investigation was to
examine the effects of high fat diet induced obesity on CRC. In this study, male
C57BL/6 mice were fed a novel high fat diet, designed to mimic the standard American
diet (12 % saturated fat & 28 % unsaturated fat), at 4 weeks of age until 16 weeks of age
to induce obesity. At 16 weeks of age mice were exposed to the CRC protocol. Thus,
mice were obese prior to initiation of CRC. This clinically relevant model aims to mimic
the conditions of tumor initiation and progression that occurs in obese humans. Previous
studies have co-induced obesity and CRC with the AOM/DSS protocol; however, this
approach fails to account for the conditions observed in the at risk obese population prior
to the onset of colon cancer. We hypothesized that obesity induced prior to initiation of
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CRC would lead to increased severity of sickness symptoms in association with enhanced
tumorigenesis. A better understanding of the impact of obesity on CRC is necessary in
determining possible therapeutic targets and/or preventative screening and diagnostic
techniques.
.
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CHAPTER 2
MATERIALS & METHODS
2.1 ANIMALS
Male C57BL/6 mice, 4 weeks of age, were purchased from Jackson Laboratories
(Bar Harbor, ME) and cared for in the animal facility at the University of South Carolina.
They were housed four-five per cage and maintained on a 12:12-hr light-dark cycle in a
low stress environment (22°C, 50% humidity, low noise) and given food and water ad
libitum. All animal experimentation was approved by the University of South Carolina's
Institutional Animal Care and Use Committee.
2.2 DIETS
Mice were randomly assigned to one of five treatment groups as follows: 1) Low
Fat Diet-Control (LFD-Con), 2) High Fat Diet-Control (HFD-Con), 3) Low Fat DietColorectal Cancer (LFD-CRC), 4) High Fat Diet-Colorectal Cancer Group 1(HFD-CRC1) or 5) High Fat Diet-Colorectal Cancer Group 2 (HFD-CRC-2). HFD-CRC-1 and
HFD-CRC-2 differed in the dose of azoxymethane (AOM) that was administered to
initiate the cancer; group 1 received a dose of AOM based on body weight (10mg/Kg)
whereas group 2 received a dose of AOM that was equivalent to the LFD-CRC group.
This was done in order to eliminate any potential differences among the groups due to the
dose of AOM. The HFD (12% saturated fat & 28% unsaturated fat) was designed to
mimic the standard American Diet (Bio-Serv, Frenchtown, NJ) (Table 2.1). The AIN76A diet was used as the LFD (Bio-Serv). Diets were administered beginning at 4 weeks
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of age through sacrifice at 26 weeks of age. The HFD retained the same vitamin and
mineral content as the control diet. Food and water was available ad libitum and
measured on a weekly basis.
2.3 BODY WEIGHT & BODY COMPOSITION
Body weight was examined weekly beginning at 4 weeks of age and for the
duration of the 22 week study. In addition, body composition was assessed at 16 weeks
of age (prior to initiation of the CRC protocol) and at 26 weeks of age (prior to sacrifice).
For this procedure, mice were placed under brief anesthesia (isoflurane inhalation) and
were assessed for lean mass, fat mass, and body fat percentage via dual-energy x-ray
absorptiometry (DEXA) (Lunar PIXImus, Madison, WI).
2.4 COLORECTAL CANCER PROTOCOL
To induce colorectal cancer, mice in the CRC groups underwent a standard
protocol consisting of a single subcutaneous injection of azoxymethane (AOM) at 16
weeks of age, followed by 3 cycles of DSS (2% DSS in water for one week followed by
two weeks of regular water for the first cycle and 1% DSS in water for the second and
third cycles) beginning at week 17. Both the LFD-CRC and the HFD-CRC-1 groups
received a dose of AOM based on their body weight (10mg/Kg body weight) whereas
HFD-CRC-2 received a dose of AOM that was equivalent to the LFD-CRC group. As
mentioned above, this was done in order to eliminate any potential differences among the
groups due to the dose of AOM (i.e. an increase in tumor number with HFD that may be
due to the increased concentration of AOM that was administered to these mice given
their increased weight).
2.5 SYMPTOM SCORING
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Symptoms were scored twice weekly throughout the 10 week protocol using a
standard scoring system that has previously been used in this model. Briefly, scores were
based on diarrhea, blood in stools and weight loss. Diarrhea symptoms were evaluated
based on visualization of the fecal matter. Blood in the stools was determined using a
Hemoccult Fecal occult blood test. Weight loss was based on the percent change in
weight compared to baseline levels. Mice were given scores of 0, 2 or 4 depending on
the severity of the symptoms.
2.6 SACRIFICE & TISSUE COLLECTION
At 26 weeks of age, mice were sacrificed for tissue collection via isofluorane
overdose. The kidney fat, mesenteric fat and epididymal fat were removed, weighed, and
immediately snap-frozen in liquid nitrogen and stored at -80°C. The large intestine was
dissected from the cecum to the anus and placed on filter paper. A large needle and
syringe was used to flush the large intestine with PBS. The large intestine was then cut
longitudinally, flattened with a cotton swab saturated with PBS, and another filter paper
was placed on top of the sections. The filter paper was then sandwiched between two
pieces of blotting paper, clipped together on all four sides, and subsequently fixed in 10%
formalin for at least 24 hours. After that time, the sections were transferred and stored in
70% ethanol at room temperature to be further analyzed for tumor number and size.
2.7 TUMOR COUNTS
To count tumors, the large intestines were rinsed in deionized water, and briefly
stained in 0.1% methylene blue. Tumors were counted by the same blinded technician
for all samples under a dissecting microscope, using tweezers to pick through the villi to
identify tumors. Tumors were classified as being greater than 2mm, less than 2mm but
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greater than 1mm, or less than 1mm in diameter using an ocular micrometer. Colon
lengths were measured as an indicator of inflammation; a shorter colon length is
indicative of greater inflammation. Similarly, colon weight was determined as an
increase in colon weight has been associated with elevated inflammation.

7

Table 2.1 Diet composition of treatment diets
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CHAPTER 3
RESULTS
3.1 BODY WEIGHT & BODY COMPOSITION
Body composition was calculated by DEXA and lean mass, percent lean mass,
total body fat, and body fat percent were determined (Figure 3.1). The mice consuming
the HFD had significantly elevated body fat and percent body fat relative to LFD-fed
mice by 16 weeks of age (following 12 weeks of HFD feedings and prior to initiation of
CRC), thus HFD-fed mice were obese prior to induction of CRC at 16 weeks of age
(P≤.05). While we observed a general increase in lean mass at sacrifice compared to
baseline for all groups, the percent lean mass for HFD-fed mice was significantly reduced
relative to the LFD-fed mice (P≤.05). Conversely, body fat and percent body fat at
sacrifice were significantly increased versus baseline in all the HFD groups.
Interestingly, at sacrifice the LFD-CRC mice had significantly lower body fat and body
fat percent than the LFD-Con, but the HFD-CRC-1 & 2 mice had significantly increased
body fat and body fat percent compared to HFD-Con mice.
Body weight was monitored twice weekly throughout the 10 week AOM/DSS
protocol and was expressed as a percent of baseline (i.e. normalized to measured body
weight prior to the initiation of the AOM/DSS protocol) (Figure 3.2A). The LFD-Con
and HFD-Con groups maintained a greater rate of body weight gain during the course of
treatment and these groups were different from each other at most time-points. However,
as expected, an overall decrease in body weight in the LFD-CRC group was observed
9

from weeks 17.5 to 22 and was significantly different from all other groups (P≤.05). The
HFD-CRC-1 & 2 groups had a significantly greater increase in percent change in body
weight than the LFD-CRC group from 17.5 weeks to 22 weeks (P≤.05).
3.2 SYMPTOM SEVERITY
Symptom scores were calculated twice weekly throughout the 10-week protocol
and were based on diarrhea, blood in stools and body weight loss (Figure 3.2B).
Symptom scores in all groups followed the same general trend; there was an increase in
symptom score during each week of DSS treatment, which dropped in the subsequent 2
weeks during the water cycle. The only significant increase in symptom severity score
was observed in LFD-CRC mice compared to HFD-CRC-2 mice at week 18.5 (P≤.05).
3.3 FOOD & FLUID INTAKE
It was not possible to calculate individual food intake, as mice were housed 45/cage. However, in general, we did not observe any differences among the HFD-fed
mice in weekly food intake (i.e food consumed by mice in each cage/number of mice in
cage) over the course of the study.
3.4 TISSUE WEIGHTS
Fat pads were collected at sacrifice and for all fat pad depots, the HFD-fed mice
had enhanced fad pad mass compared to the LFD-fed mice (Figure 3.3) (P≤.05). Both
HFD-CRC-1 & 2 groups had a significantly greater epididymal fat pad mass than HFDCon mice; however, the HFD-CRC-1 & 2 groups had reduced mesentery fat pads relative
to HFD-Con.
Spleens were collected and weighed at sacrifice (Figure 3.4). In general, spleen
weight, expressed as a percent of body weight, increased in all CRC groups as compared
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to the control HFD and LFD mice and this reached significance when LFD-CRC mice
were compared to HFD-Con mice (P≤.05).
3.5 TUMOR COUNTS
At sacrifice, colons were harvested and tumors were counted on formalin-fixed,
methylene blue-stained sections.

No significant differences between groups were

determined; however, the number of polyps in the LFD-CRC and HFD-CRC-2 groups
was elevated compared to HFD-CRC-1 (Figure 3.6). Colon length and weight were
measured following fixation. No significant differences were observed between groups
for colon length and colon weight, (Figure 3.5).
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Figure 3.1 DEXA body composition collected at baseline (16 weeks of age) and at
sacrifice (26 weeks of age) on (A) lean mass and BMC, (B) body fat, (C) % lean mass
and BMC, (D) % body fat. *Significantly different from LFD
LFD-Con (P≤.05).
.05).
#Significantly different from HFD-Con (P≤.05).
.05). $Significantly different from LFDLFD
CRC (P≤.05)
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Figure 3.2 The impact of HFD and CRC on (A) percent change in body weight.
*Significantly different from LFD-Con (week 17.5-18: HFD-Con & LFD-CRC; week
18.5-19: HFD-Con, LFD-CRC, & HFD-CRC-1 & 2; week 19.5-21.5: HFD-Con, LFDCRC, & HFD-CRC-1; week 22-24.5: HFD-Con & LFD-CRC; week 25-26: HFD-Con,
LFD-CRC, & HFD-CRC1&2; P≤.05) #Significantly different from HFD-Con (week
16.5-17: LFD-CRC; week 17.5-26: LFD-CRC & HFD-CRC-1&2; P≤.05).
$Significantly different from LFD-CRC (week 17.5-26: HFD-CRC-1&2; P≤.05). (B)
The effect of DSS induced inflammation on symptom scores. $Significantly different
from LFD-CRC (week 18.5: HFD-CRC-2 only; P≤.05)

13

Figure 3.3 The effect of HFD and CRC on (A) epididymal, (B) mesentery,
(C) kidney, and (D) total visceral (Total) fat pad weights at sacrifice.
*Significantly different from LFD-Con (P≤.05). #Significantly different from
HFD-Con (P≤.05). $Significantly different from LFD-CRC (P≤.05)
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Figure 3.4 Spleen weight at sacrifice as a measure of inflammation and CRC
immune response. #Significantly different from HFD-Con (P≤.05)
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Figure 3.5 The effect of CRC and DSS induced inflammation on (A) colon length
and (B) colon weight. *Significantly different from LFD-Con (P≤.05).
#Significantly different from HFD-Con (P≤.05). $Significantly different from
LFD-CRC (P≤.05)
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Figure 3.6 The impact of CRC induction at sacrifice for (A) total polyp number & (B)
total polyp number by size. No significant differences between any groups
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Figure 3.7 Mean (A) food consumption & (B) water consumption per group.
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CHAPTER 4
DISCUSSION
CRC is the second leading cause of cancer related deaths worldwide and is a
serious public health concern. Lifestyle factors, such as obesity, smoking, high caloric
intake and physical inactivity, have been linked to increased mortality in CRC cases and
are controllable factors in the prevention of CRC development and progression 7.
Clinical studies suggest that up to 20% of all cancers are attributed to obesity. Further, it
has been well characterized that obesity is widely correlated with the incidence of CRC 7.
In addition, obesity is largely responsible for poorer oncologic outcomes in CRC
treatment and management 7. Our novel study examined the impact of HFD-induced
obesity in a mouse model of CRC by initiating obesity prior to colon carcinogenesis and
is thus, clinically relevant to the human obese population at risk for developing CRC.
However, we did not find any significant changes in tumor number or size with obesity.
Similarly, obesity did not increase the severity of symptoms in this model.
Currently, AOM/DSS-induced carcinogenesis in animal models is widely
accepted and offers a reliable, reproducible, and time-effective approach for the study of
colonic tumorigenesis 7. Previous studies have utilized this model to investigate the link
between obesity and colonic/colitis-related carcinogenesis. It is well established that
adipocytes regulate inflammatory processes and secrete proinflammatory cytokines,
which have been linked to increased proliferation of colonic epithelial cells and
facilitation of a microenvironment prone to tumor development 8. For example, Park et
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al. showed that HFD induced obesity in a colitis-related tumorigenesis model increased
tumor formation and revealed that adiposity-associated inflammation contributes to
colonic epithelial cell carcinogenesis 9. In addition, the AOM/DSS model has been
widely used to explore potential chemopreventive and therapeutic agents in the treatment
of obesity and colitis-related colonic carcinogenesis 8.
In our study, male C57BL/6 mice were fed either a LFD (AIN-76A) or HFD
(12% saturated fat and 28% unsaturated fat) at 4 weeks of age and placed in one of five
groups (LFD-Control, HFD-Control, LFD-CRC, HFD-CRC-1, and HFD-CRC-2). The
HFD was designed to be similar to the American standard diet; we previously
demonstrated that this diet led to increased adiposity, macrophage infiltration, and insulin
resistance in obese mice 10. As such, in our study, we observed that at 16 weeks of age
the HFD-fed mice had significantly increased mean body mass compared to LFD-fed
mice, thus were obese prior to administration of AOM/DSS treatment (P≤.05). Enos et
al. and others have shown that varying saturated fatty acid composition leads to an
increased risk of obesity and can differentially regulate inflammatory processes, thus it is
now widely accepted that high-fat-diet-induced obesity can lead to a chronic state of lowgrade inflammation 10. Although inflammatory processes were not measured in the
current investigation, we expected that obesity-induced inflammation following
administration of this diet, would contribute to the hypothesized effects of increased
tumorigenesis with obesity.
DSS, a proinflammatory agent, accelerates tumor growth and proliferation when
instituted following an intraperitoneal injection of AOM by promoting cell growth in the
epithelial lining of the colon while also halting apoptosis 7. Similarly, inflammation, as
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seen in inflammatory bowel disease and Crohn’s disease, also contribute to the
development of CRC through various mechanisms that disrupt cellular function and
regulation 11. We observed in the weeks following treatment with DSS that the sickness
symptoms in all the AOM/DSS groups was lower than expected and remained diminished
over the remainder of the study. This decrease in sickness symptoms over time is
consistent with previous reports; in a comprehensive review by De Robertis et al., it was
reported that severe colitis is observed in the week following initial administration of
DSS but its severity is diminished in subsequent weeks 7. Contrary to expectations
though, we did not find an increase in symptom severity in the HFD groups. Similarly, at
sacrifice, the colon length in the AOM/DSS treated groups did not decrease, suggesting
little to no inflammation. A decrease in colon length is a characteristic feature observed
in an inflamed colon, therefore these findings were unexpected. Further, tumor number
was quite low and there were no differences in tumor size or tumor numbers with HFD.
In a recent series of studies we conducted on colitis-related colon carcinogenesis, 2%
DSS was administered in all three treatment cycles; however, a high number of fatalities
prior to sacrifice limited the scope of the study. In this study, we subsequently reduced
the dosage of DSS to 2%, 1%, and 1% at weeks 17, 20, and 23, respectively; however,
contrary to what was expected, we found tumor numbers to be lower than those reported
in the literature. These findings of a failure to find a detrimental effect of obesity on
tumorigenesis in this model should be interpreted with caution; it is certainly possible
that low tumor numbers precluded our ability to find changes in tumor characteristics
across the groups.
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A possible explanation for the discrepancy in inflammation and CRC tumor
development may be the difference in the dosage of DSS. It has been established that the
risk of developing CRC is positively correlated with the degree of inflammation within
the colon and the duration of the inflammatory disease state. A DSS dosage study
conducted with AOM-induced CRC carcinogenesis reported that 2% DSS treatment
resulted in the highest number of colorectal adenocarcinomas 12. Similarly, it was also
reported that inflammation scores were higher in mice receiving 2% DSS, suggesting
there is a tumor-promoting activity in DSS 12. As inflammation is necessary in the
induction of tumor formation, this may help to explain the minimal number of tumors
observed in our model. In addition, it is worthwhile mentioning that the body weight and
age of mice at time of AOM/DSS treatment were greater than those reported in previous
models, which may have also contributed to the observed findings. Another possible
rationale for the inconsistent tumor number and inflammatory symptom severity may be
due to the extent of excess fat accumulation at the time of AOM/DSS treatment. While
obesity is generally understood to have a proinflammatory effect in the colon, our results
suggest that obesity may have some protective role in the initiation of CRC. This affirms
the need for future research utilizing HFD-induced obesity models to better understand
the relationship between obesity and colorectal tumorigenesis.
In summary, we examined the influence of HFD-induced obesity on
inflammatory-mediated colorectal tumorigenesis, tumor proliferation, and symptom
severity. In general, there was no increase in symptom severity with HFD-induced
obesity. Similarly, in regard to tumor number, our findings are contradictory to
previously published data that ad libitum, high-fat diet induced obesity leads to an
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increased risk of CRC development. However, our findings should be interpreted with
caution; it is certainly possible that low tumor numbers precluded our ability to find
changes in tumor characteristics and symptom severity with obesity. Although obesity
has implications of having proinflammatory and carcinogenic outcomes in the colon,
future research should examine the degree to which HFD induced obesity impacts
metabolic disruption, pro-inflammatory signaling, and subsequent initiation and
proliferation of CRC as well as determine the pro-oncogenic factors involved in this
process.
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